TY - JOUR
T1 - CPX-351 (vyxeos) in AML
AU - Alfayez, Mansour
AU - Kantarjian, Hagop
AU - Kadia, Tapan
AU - Ravandi-Kashani, Farhad
AU - Daver, Naval
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/1/28
Y1 - 2020/1/28
N2 - For decades, the standard induction for patients with acute myeloid leukemia (AML) has been the combination of cytarabine with anthracycline (7 + 3 regimen). In August 2017 the US FDA approved CPX-351 (vyxeos), a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio, for the treatment of adults with newly diagnosed AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML). This is the first approved treatment specifically for patients with this subgroup of AML. The approval was based on findings from a multicenter, randomized, open-label, phase III study of CPX-351 Versus 7 + 3 in patients 60–75 years old with newly diagnosed AML-MRC or t-AML. In this study CPX-351 had a higher median OS than 7 + 3 (9.56 vs 5.95 months, HR 0.69; 95% CI: 0.52 to 0.90, p = 0.005). In this profile, we review preclinical and clinical data, and discuss limitations and future directions with CPX-351 use in AML.
AB - For decades, the standard induction for patients with acute myeloid leukemia (AML) has been the combination of cytarabine with anthracycline (7 + 3 regimen). In August 2017 the US FDA approved CPX-351 (vyxeos), a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio, for the treatment of adults with newly diagnosed AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML). This is the first approved treatment specifically for patients with this subgroup of AML. The approval was based on findings from a multicenter, randomized, open-label, phase III study of CPX-351 Versus 7 + 3 in patients 60–75 years old with newly diagnosed AML-MRC or t-AML. In this study CPX-351 had a higher median OS than 7 + 3 (9.56 vs 5.95 months, HR 0.69; 95% CI: 0.52 to 0.90, p = 0.005). In this profile, we review preclinical and clinical data, and discuss limitations and future directions with CPX-351 use in AML.
KW - AML in elderly
KW - AML-MRC
KW - CPX-351
KW - Vyxeos
KW - sAML
KW - t-AML
UR - http://www.scopus.com/inward/record.url?scp=85078385782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078385782&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1660970
DO - 10.1080/10428194.2019.1660970
M3 - Review article
C2 - 31547736
AN - SCOPUS:85078385782
SN - 1042-8194
VL - 61
SP - 288
EP - 297
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -